With 1 mL bacteriostatic water
2.0 units
Page last checked
Reconstitution · Hexarelin
Hexarelin reconstitution calculator
Pick the vial, the water you added and the dose. Get the exact draw in units for the syringe in your hand.
Step 1 of 4
- total mg in the calculation
- mL used in the calculation
- mcg
This vial holds 5,000 mcg in total.
- match the size on the package
U-100 insulin syringe · 1 mL · lines every 2 units · 1 unit = 0.01 mL
Draw to
4.0units
4.0 units on a U-100 insulin syringe · 1 mL · lines every 2 units, which is 0.04 milliliters. The draw lands on a syringe line.
5 mg ÷ 2 mL = 2.50 mg/mL
→ 25 mcg/unit · 100 mcg = 0.040 mL = 4.0 units
→ 25 mcg/unit · 100 mcg = 0.040 mL = 4.0 units
Your address is used to send this one card. The email also includes an optional link for updates when our data changes. Nothing else is sent unless you choose that link, and you can unsubscribe anytime.
Show the math and syringe details
Can this syringe show the result clearly?
Want an easier syringe number?
How to use the calculator
- 1
Enter the amount in the vial
- 2
Enter the water you added
- 3
Enter the dose you want to convert
Hexarelin is a peptide six amino acids long, built in the early 1990s to trigger a growth-hormone pulse. Sellers pitch it as the hardest-hitting of the growth-hormone peptides, for muscle and recovery.
The pulse gets smaller as the doses repeat. On the only long course on record it had roughly halved by week 16, and came back only once the drug stopped. No trial turned that into a schedule, and none measured muscle.
Examples using 5 mg of Hexarelin
Each row uses 5 mg and the liquid volume shown. Dividing the amount by that volume gives the calculated concentration. The rows are arithmetic examples, not alternative product preparations.
◆ How liquid volume changes the resultdose used: 100 mcg
With 2 mL bacteriostatic water
4.0 units
| Bacteriostatic water | Concentration | Per U-100 unit | Draw for 100 mcg | Nearest syringe line |
|---|---|---|---|---|
| 1 mL | 5.00 mg/mL | 50.0 mcg | 2.0 u · 0.020 mL | exactly 2 u |
| 2 mL | 2.50 mg/mL | 25.0 mcg | 4.0 u · 0.040 mL | exactly 4 u |
The amount, liquid volume and dose shown here are the calculator’s starting example for Hexarelin. Replace them with your own values. Every result in the table is calculated from those inputs.
Hexarelin: small calculated draws make syringe spacing important
The hexarelin presets can produce small liquid volumes at the starting amount. A printed syringe interval may then represent a noticeable share of the draw. The target volume and the nearest marked reading are separate results.
Open the mixing details3 notes
A rounded reading is not the exact target
The syringe graphic shows where the calculated volume falls on the selected scale. When that position sits between markings, the rounding output explains the difference. More digits in the calculation cannot make the printed scale more detailed.
Changing vial strength or water volume can move the target along the barrel. That illustrates concentration, not a recommendation to choose a particular preparation. After changing inputs, the new rounding result belongs to the new setup.
Hormone findings do not choose a course length
The longer hexarelin study described in the guide measured a hormone response that changed during the study and after stopping. That is evidence about the measured response in that protocol, not an instruction for planning an individual course.
A vial-life estimate counts theoretical draws at an entered amount and frequency. It cannot use a hormone result to select that frequency, decide when treatment should end or establish how long a mixed preparation remains usable.
Weight-based study figures differ from reported flat amounts
The guide separates study amounts expressed per kilogram from reported flat amounts. A per-kilogram value is not the total quantity given to a participant. Those units need to stay attached when a figure is read or copied.
The calculator converts a total amount into a volume. It does not decide which evidence applies or infer a suitable amount from a hormone response. A clean conversion therefore remains distinct from the question of whether the input is appropriate.
Hexarelin’s human studies kept body weight in the dose
Some cited hexarelin studies used injections under the skin; another used an intravenous dose. Their amounts were based on body weight. Even where the route matches, a trial’s per-kilogram figure is not a flat dose for the tool.
Read the supporting evidence3 supporting notes
More frequent dosing did not raise every measured hormone
A short study compared two daily injections with three. Both schedules raised growth hormone to a similar extent, without changing IGF-I. That finding describes the study’s measurements; it does not establish a preferred personal schedule.
The response changed during the longer course
The longer study found that the growth-hormone response declined during treatment and recovered after it stopped. It did not show significant changes in body fat or lean mass. An initial hormone response is therefore an incomplete account of the results.
Keep trial amounts separate from reported use
The fixed amounts reported in practice have a different basis from the weight-based trial doses. The tool converts whichever mass is entered; it does not make those sources equivalent.
More frequent dosing did not raise every measured hormone
A short study compared two daily injections with three. Both schedules raised growth hormone to a similar extent, without changing IGF-I. That finding describes the study’s measurements; it does not establish a preferred personal schedule.
The response changed during the longer course
The longer study found that the growth-hormone response declined during treatment and recovered after it stopped. It did not show significant changes in body fat or lean mass. An initial hormone response is therefore an incomplete account of the results.
Keep trial amounts separate from reported use
The fixed amounts reported in practice have a different basis from the weight-based trial doses. The tool converts whichever mass is entered; it does not make those sources equivalent.
Units to dose at 2.50 mg/mL
Mix 5 mg into 2 mL and one U-100 unit carries 25.0 mcg. The table shows how much peptide is in each numbered syringe line. These are conversion examples, not suggested doses.
Open the unit conversion table10 rows
| U-100 line | Volume | Mass (mcg) | Mass (mg) |
|---|---|---|---|
| 10 u | 0.10 mL | 250 mcg | 0.25 mg |
| 20 u | 0.20 mL | 500 mcg | 0.5 mg |
| 30 u | 0.30 mL | 750 mcg | 0.75 mg |
| 40 u | 0.40 mL | 1,000 mcg | 1 mg |
| 50 u | 0.50 mL | 1,250 mcg | 1.25 mg |
| 60 u | 0.60 mL | 1,500 mcg | 1.5 mg |
| 70 u | 0.70 mL | 1,750 mcg | 1.75 mg |
| 80 u | 0.80 mL | 2,000 mcg | 2 mg |
| 90 u | 0.90 mL | 2,250 mcg | 2.25 mg |
| 100 u | 1.00 mL | 2,500 mcg | 2.5 mg |
How the math works
- Concentration — divide the amount entered by the liquid volume used in the calculation: mg ÷ mL = mg/mL. This tells you how many mg are in each mL.
- Volume — the dose divided by that concentration: dose ÷ (mg/mL) = mL.
- Units — on a U-100 syringe one unit is 0.01 mL, so mL × 100 = units. A U-40 unit is 0.025 mL, so the wrong barrel is a 2.5× error. That is why the calculator asks which one you have.
- Rounding gap — the exact draw against the nearest syringe line: |exact − nearest line| ÷ exact × 100 = % difference.
Useful guides for this calculation
The math is only one part of the question. These guides cover the compound, published doses, side effects, mixing steps and supplies.
- Rahim A, O’Neill PA, Shalet SM. Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab 1998;83(5):1644-9retrieved 2026-08-12Human trial
- Maccario M, Veldhuis JD, Broglio F, Di Vito L, Arvat E, Deghenghi R, Ghigo E. Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans. Eur J Endocrinol 2002;146(3):310-8retrieved 2026-08-12Human trial
- Massoud AF, Hindmarsh PC, Brook CG. Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study. J Clin Endocrinol Metab 1996;81(12):4338-41retrieved 2026-08-12Human trial
- Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol 2026 — tabulates self-reported online dosing patterns beside the clinical doses, stating the reported values must not be read as clinically validated, regulatory-approved or saferetrieved 2026-08-12indirect evidence